A Phase 1/2 interventional study of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) and high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in COVID-19, sponsored by National Vaccine and Serum Institute, China. Completed at 1 site in China. Open to participants aged 3 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-16.
Sponsored by National Vaccine and Serum Institute, China (part of Sinopharm) · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing CHO cell in COVID-19 — 1 open to participants now, 1 under way, none of them phase 3. CHO cell · COVID-19.
Among the 18 studies testing CHO cell in COVID-19, this one is the 4th largest by enrollment, is one of 9 that started in 2021, is the only one in phase 1/2, and was the 5th registered.
7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.
Browse COVID-19 studies →1 of the 18 studies testing CHO cell in COVID-19 is open now, in 1 country. Recruiting first, the newest first:
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · Sites in China
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 3 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 7 · Phase 4 1
First in 2020; this study’s year is marked. 9 started in 2021.
This study's enrollment of 3,100 is above the median of 102 across 4,366 interventional studies indexed under COVID-19.
Median enrollment 714 across the 18 interventional studies. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 18 have an industry lead sponsor. The 5 most frequent:
This study is registered under National Vaccine and Serum Institute, China, one of the names counted as Sinopharm. Under that name alone:
National Vaccine and Serum Institute, China is the lead sponsor of 13 studies on the registry; none are open to participants now.
28 studies in COVID-19 by Sinopharm: none open now, 4 under way, 2 of them phase 3. Of 6 finished, 0 (0%) have results posted.
Among the 28 studies in COVID-19 by Sinopharm, this one is the 5th largest by enrollment, is one of 17 that started in 2021, is one of 3 in phase 1/2, and was the 3rd registered.
Sinopharm’s COVID-19 studies by the year they started, since 2020.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing CHO cell in COVID-19, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sinopharm’s 28 in COVID-19:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
phase I study will evaluate safety and immunogenicity of a recombinant SARS-CoV-2 vaccine (CHO cell) in Chinese healthy population aged 3 years and older. 300 subjects will be enrolled and divided into 5 age groups: 18-59 years old group, 60-69 years old group, ≥70 years old group, 9-17 years old group and 3-8 years old group. In each group, there are two regimen cohort: low-dose at 0,30, 60 schedule and high-dose at 0,30,60 schedule. The subjects in regimen cohort will be randomized to receive vaccines or placebos at a ratio of 2:1.
Phase II clinical study will explore dose and immunization procedures in 5 age groups, including 18-59 years old group, 60-69 years old group, ≥70 years old group, 9-17 years old group, and 3-8 years old group, with a total of 3280 subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
First Dose Exclusion Criteria:
Exclusion criteria for the second and third doses of vaccination
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
Biological: high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
Biological: placebo
Biological: low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
Biological: low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
Biological: low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
Biological: low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
Biological: high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
Biological: high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
Biological: high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
Biological: high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
Biological: placebo
Biological: placebo
Biological: placebo
Biological: placebo
Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
Intramuscular injection of high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
Intramuscular injection of placebo in the deltoid muscle of the upper arm
the incidence and severity of any adverse reactions/events within 30 minutes after each dose of vaccination
Phase 1
Time frame: through 30 minutes after each dose
the incidence of abnormal blood biochemistry, blood routine, blood coagulation function and urine routine on the 4th day after each dose of vaccination
Phase 1
Time frame: 4th day each dose
the incidence and severity of adverse reactions/events within 0-7 days after each dose of vaccination
Phase 1
Time frame: through 7 days after each dose
the incidence and severity of non-collective adverse reactions/events within 30 days after each dose of vaccination
Phase 1
Time frame: through 30 days after each dose
the incidence and severity of adverse events leading to withdrawal within 30 days after each dose of vaccination
Phase 1
Time frame: through 30 days after each dose
the incidence of SAE from the first dose of vaccination to 12 months after the full course of vaccination
Phase 1
Time frame: up to 12 months after the full course of vaccination
the incidence of AESI from the first dose of vaccination to 12 months after the full course of vaccination
Phase 1
Time frame: up to 12 months after the full course of vaccination
Geometric mean Titer of SARS-CoV-2 specific neutralizing antibody(wild Strains) on the 15th day after the full course of vaccination
Phase 1
Time frame: 15th day after the full course of vaccination
the incidence and severity of any adverse reactions/events within 30 minutes after each dose of vaccination
Phase 2
Time frame: through 30 minutes after each dose
the incidence and severity of adverse reactions/events within 0-7 days after each dose of vaccination
Phase 2
Time frame: through 7 days after each dose
the incidence and severity of non-collective adverse reactions/events within 30 days after each dose of vaccination
Phase 2
Time frame: through 30 days after each dose
the incidence and severity of non-collective adverse reactions/events within 40 days after each dose of vaccination
Phase 2
Time frame: through 40 days after each dose
the incidence and severity of non-collective adverse reactions/events within 60 days after each dose of vaccination
Phase 2
Time frame: through 60 days after each dose
the incidence and severity of adverse events leading to withdrawal within 30 days after each dose of vaccination
Phase 2
Time frame: through 30 days after each dose
the incidence and severity of adverse events leading to withdrawal within 40 days after each dose of vaccination
Phase 2
Time frame: through 40 days after each dose
the incidence and severity of adverse events leading to withdrawal within 60 days after each dose of vaccination
Phase 2
Time frame: through 60 days after each dose
the incidence of SAE from the first dose of vaccination to 12 months after the full course of vaccination
Phase 2
Time frame: up to 12 months after the full course of vaccination
the incidence of AESI from the the first dose of vaccination to 12 months after the full course of vaccination
Phase 2
Time frame: up to 12 months after the full course of vaccination
Geometric mean Titer of SARS-CoV-2 specific neutralizing antibody (wild Strains) on the 15th day after the full course of vaccination
Phase 2
Time frame: 15th day after the full course of vaccination
Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (Live SARS-CoV-2 neutralization assay) On the 30th day after the full course of vaccination, the neutralizing antibody level (wild Strains)
Phase 1
Time frame: 30th day after the full course of vaccination
Seroconversion and Geometric Mean Titer (GMT) of SARS-CoV-2-Specific Binding Antibody (IgG) Before each dose, the 15th day after the second dose, the 15th, 30th, 90th, 180th, 360th day after full course of vaccination
Phase 1
Time frame: before each dose , the 15th day after the second dose, the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination
Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (Pseudovirus neutralization assay) in the 18-59 years old group before each dose and on the 15th and 30th day after the full course of vaccination
Phase 1
Time frame: before each dose,the 15th, 30th day after the full course of vaccination
Geometric Mean Titer (GMT) of SARS-COV-2 specific neutralizing antibody (live SARS-CoV-2 neutralization assay)) On the 30th day after the full course of vaccination
Phase 2
Time frame: 30th day after the full course of vaccination
Two-dose group: the neutralizing antibody levels (live SARS-CoV-2 neutralization assay) before each dose,the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination
Phase 2
Time frame: before each dose,the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination
Two-dose group: Seroconversion before each dose,the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination
Phase 2
Time frame: before each dose,the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination
Two-dose group: Binding Antibody (IgG) before each dose,the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination
Phase 2
Time frame: before each dose,the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination
Three-dose group: the neutralizing antibody levels (live SARS-CoV-2 neutralization assay) before each dose,the 15th day after the second dose, the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination
Phase 2
Time frame: before each dose,the 15th day after the second dose, the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination
Three-dose group:Seroconversion before each dose,the 15th day after the second dose, the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination
Phase 2
Time frame: before each dose,the 15th day after the second dose, the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination
Three-dose group:Binding Antibody (IgG) before each dose,the 15th day after the second dose, the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination
Phase 2
Time frame: before each dose,the 15th day after the second dose, the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination
Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (Pseudovirus neutralization assay) in the 18-59 years old 0,30,60 group before each dose , the 15th and 30th day after the full course of vaccination
Phase 2
Time frame: before each dose, 15th, 30th day after the full course of vaccination
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2021 to primary completion in Aug 2023, 28 months.
Of 80 industry-sponsored phase 1/2 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 28 months is above that.
Counting every sponsor, half of 187 studies reached it within 11 months; a quarter within 4 and three quarters within 20.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CHO cell
National Vaccine and Serum Institute, China →